VRB-101 Phase 3 first dose
Verdiva’s EVOLVE-2 update makes planned Phase 3 initiation conditional on positive Phase 2b results. Its once-weekly oral formulation is not equivalent to injectable ecnoglutide studies.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Current private investment classification is explicitly supported by investor RA Capital; recheck before activation.
- The stated 2027 plan is conditional and may change; do not turn it into an unconditional scheduled launch.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Conditional company target: 2027; exact date unconfirmed
Company context
An official company source identifies the company as privately held. This is source-reported context, not independent legal-registry verification; recheck ownership, listing and acquisition status before any market listing.
Potential outcome market
Will a participant receive oral VRB-101 in a designated Phase 3 obesity trial by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.